Eyevensys Names Ronald Buggage as Chief Medical Officer

September 8, 2017: By Jon Swedien

eyevensysEyevensys has appointed Ronald Buggage, MD, its chief medical officer, the French company announced Sept. 4.

Eyevensys is a private clinical stage biotech company based in Paris. The company is developing its proprietary EyeCET platform, which it says is the first non-viral gene expression technology that enables safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases.

Buggage will drive the company’s drug development strategy, overseeing clinical development programs for a broad range of ophthalmic indications based on the EyeCET platform.

Buggage was most recently division medical officer at Sanofi’s Ophthalmology Unit, Eyevensys said. He was responsible for coordination of medical and scientific activities for Sanofi’s ophthalmology portfolio, including development programs for ocular gene therapy.

He has also served as chief scientific officer at Novagali Pharma, where he was responsible for the global clinical and regulatory strategy.

Buggage has also held positions in clinical development at Novartis and Pfizer. He obtained his doctorate at the UCLA School of Medicine and specialized in ophthalmology at Emory University. He completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022